[ Symic Biomedical raises $30M in Series B ]

Symic Biomedical has raised $30 million in Series B funding.

Founded in 2012, Symic Biomedical operates in the healthcare industry focusing on biotechnology business. It develops pipeline products for targeting the extracellular matrix.

The company  will use the new financing to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures.

Funding  Series B
Founded  2012
Country  USA
City  Emeryville, California
Founder / CEO  Kenneth N. Horne
Deal Size  $30M
Investors  HEDA Ventures
Previous Investors  Lilly Ventures
 Mitsui Global Investment
 National Institutes of Health
 HEDA Ventures